PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.30%
Cash & equivalents growing 6.30% while Medical - Pharmaceuticals shows decline of -4.53%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
6.30%
Below half the Medical - Pharmaceuticals median of -5.74% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
35.35%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-2.20%
Inventory growth less than half of Medical - Pharmaceuticals median of 1.46%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
51.68%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
3.13%
Below half the Medical - Pharmaceuticals median of -2.25%. Jim Chanos would question if the company faces working capital strain.
2.80%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-0.46%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.46%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-79.21%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-310.43%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
158.53%
Above 1.5x Medical - Pharmaceuticals median of 0.04%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.68%
Below half the Medical - Pharmaceuticals median of -0.68%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
2.82%
Below half the Medical - Pharmaceuticals median of -0.91%. Jim Chanos might see potential stagnation or distress vs. peers.
2.45%
Payables growth below half of Medical - Pharmaceuticals median of 6.57%. Joel Greenblatt sees more conservative payables management vs. peers.
-5.12%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-30.41%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-80.81%
≥ 1.5x the Medical - Pharmaceuticals median of -6.02%. Joel Greenblatt sees a robust subscription base vs. peers.
138.83%
Above 1.5x Medical - Pharmaceuticals median of 0.03%. Jim Chanos suspects a potential short-term burden spike.
3.49%
Below half Medical - Pharmaceuticals median of -1.58%. Joel Greenblatt sees more conservative short-term leverage than peers.
-10.83%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
100.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger extended contract coverage.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
82.01%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.85%
Above 1.5x Medical - Pharmaceuticals median of -1.29%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
3.10%
Below half Medical - Pharmaceuticals median of -0.30%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.69%
Below half Medical - Pharmaceuticals median of -1.66%. Jim Chanos suspects poor profitability or large dividend drains.
40.00%
AOCI growth below half of Medical - Pharmaceuticals median -5.46%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.57%
Below half Medical - Pharmaceuticals median of -1.47%. Jim Chanos suspects slower net worth growth or losses vs. peers.
2.82%
Below half Medical - Pharmaceuticals median of -0.73%. Jim Chanos suspects a major slowdown or distress.
103325.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-57.60%
Above 1.5x Medical - Pharmaceuticals median of -0.22%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-27.83%
Below half of Medical - Pharmaceuticals median 5.44%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.